Trial Profile
A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs BMS 986012 (Primary) ; Carboplatin; Cisplatin; Etoposide; Platinum complexes
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Jan 2024 Planned End Date changed from 29 Dec 2023 to 29 Jun 2024.
- 16 Aug 2023 Planned End Date changed from 24 Aug 2022 to 29 Dec 2023.
- 25 Apr 2022 Planned End Date changed from 25 Feb 2022 to 24 Aug 2022.